Vertex announced data on on ALS-2200 are being presented at AASLD

theflyonthewall.com

Vertex Pharmaceuticals announced that data on ALS-2200, VX-135, an oral medicine Vertex is developing for the treatment of hepatitis C, are being presented for the first time at The Liver Meeting, the 63rd Annual Meeting of the American Association for the Study of Liver Diseases, AASLD. Data from viral kinetic study showed rapid reduction of HCV RNA with ALS-2200 (VX-135), Vertex’s oral nucleotide analogue in development for the treatment of hepatitis C.

View Comments (0)